Is the measles, mumps, and rubella (MMR) vaccine recommended for a mid-50s male patient?

From the Guidelines

The measles, mumps, and rubella (MMR) vaccine is recommended for a mid-50s male patient if he was born in 1957 or later and does not have documentation of 1 or more doses of MMR vaccine or laboratory evidence of immunity to each of the 3 diseases. According to the recommended adult immunization schedule: united states, 2013 1, adults born before 1957 generally are considered immune to measles and mumps. However, all adults born in 1957 or later should have documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine, or laboratory evidence of immunity to each of the 3 diseases. Some key points to consider:

• A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who are students in postsecondary educational institutions, work in a health care facility, or plan to travel internationally 1.
• Persons who received inactivated (killed) measles vaccine or measles vaccine of unknown type from 1963 to 1967 should be revaccinated with 2 doses of MMR vaccine 1.
• Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella 1. Therefore, if the mid-50s male patient does not have evidence of immunity, he should receive the MMR vaccine to protect against measles, mumps, and rubella.

From the Research

MMR Vaccine Recommendation for Mid-50s Male Patient

The recommendation for the measles, mumps, and rubella (MMR) vaccine for a mid-50s male patient can be determined based on the following points:

• According to the study 2, the Advisory Committee on Immunization Practices (ACIP) recommends 1 dose of MMR vaccine for adults aged ≥18 years who do not have evidence of immunity.
• The study 3 found that the MMR vaccine is safe for adults, with low rates of systemic adverse events and no serious adverse events reported.
• The studies 4 and 5 provide evidence on the effectiveness and safety of the MMR vaccine in children, but do not specifically address the recommendation for adults in their 50s.
• The study 6 assessed the immunogenicity and safety of a second dose of MMR vaccine in healthy participants 7 years of age or older and found that the vaccine induced robust immune responses and was well tolerated.

Key Points to Consider

• The ACIP recommends 1 dose of MMR vaccine for adults aged ≥18 years who do not have evidence of immunity 2.
• The MMR vaccine is safe for adults, with low rates of systemic adverse events and no serious adverse events reported 3.
• There is no specific recommendation for adults in their 50s, but the vaccine is recommended for adults who do not have evidence of immunity 2.

Adverse Events

• The most common solicited adverse events reported in the study 6 were injection site redness and pain, and fever.
• The study 3 found that local and systemic adverse events were more common among female travellers, but the rates of adverse events were similar between the MMR and MMRV vaccines.